Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Explore wealth building through entrepreneurship and understand how it can significantly impact your financial future and opportunities.
23,116 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
MU surged with the AI boom, then cooled. This guide asks the practical question: should micron technology stock be bo...
Epic Games cuts 1,000 jobs as Fortnite engagement wanes in a challenging market. The move highlights how live-service...
When Burke & Herbert shares jump, investors want to know why. This article breaks down what this burke herbert signal...
EdgeClear steps up in 2026 with a major platform upgrade and lower costs. This edgeclear review 2026 examines whether...
As Angiodynamics (ANGO) gears up for the 2026 earnings season, investors should focus on orders, backlog, margins, an...
Ford’s global footprint is narrowing as European and Chinese demand falters, leaving the US as the main growth engine...
Goldman Sachs and KeyBanc boosted AT&T price targets after the telecom giant unveiled a three-segment reporting model...
Oil prices surge on geopolitical tensions, lifting energy stocks. This article examines a single ETF that could benef...
Brokerages launch pilots that allow 13-year-olds to trade stocks with limited parental approval, prompting wide-rangi...
The 2027 cost-of-living adjustment is projected to be about 2.8%, continuing a pattern of modest bumps that often lag...
Analysts project XRP could climb to multi-dollar levels by 2030, but the path hinges on regulatory outcomes and Rippl...